S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
The 3-Stock Retirement Blueprint (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
The 3-Stock Retirement Blueprint (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
The 3-Stock Retirement Blueprint (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
The 3-Stock Retirement Blueprint (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
The 3-Stock Retirement Blueprint (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
The 3-Stock Retirement Blueprint (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
The 3-Stock Retirement Blueprint (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
The 3-Stock Retirement Blueprint (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:AUPH

Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

$8.27
-0.10 (-1.19%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.03
$8.51
50-Day Range
$8.14
$12.80
52-Week Range
$7.70
$33.97
Volume
3.16 million shs
Average Volume
2.92 million shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.20

Aurinia Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
156.3% Upside
$21.20 Price Target
Short Interest
Healthy
9.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.46mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.70) to ($0.11) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

933rd out of 1,293 stocks

Pharmaceutical Preparations Industry

448th out of 619 stocks

AUPH stock logo

About Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH traded down $0.10 during mid-day trading on Monday, hitting $8.27. 3,166,680 shares of the stock were exchanged, compared to its average volume of 2,917,019. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -6.95 and a beta of 0.95. The firm's 50-day simple moving average is $10.63 and its 200 day simple moving average is $12.17. Aurinia Pharmaceuticals has a fifty-two week low of $7.70 and a fifty-two week high of $33.97.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Rating) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative return on equity of 38.01%. During the same period last year, the firm earned ($0.37) earnings per share. On average, analysts predict that Aurinia Pharmaceuticals will post -0.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AUPH has been the subject of several recent research reports. Oppenheimer lowered their price target on Aurinia Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a research note on Monday. Royal Bank of Canada lowered their price target on Aurinia Pharmaceuticals from $22.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday. StockNews.com upgraded Aurinia Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday, May 23rd. HC Wainwright decreased their target price on Aurinia Pharmaceuticals from $33.00 to $30.00 in a report on Wednesday, May 4th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Aurinia Pharmaceuticals in a report on Thursday, April 28th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $21.20.

Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 15.1% Higher
Why Aurinia Pharmaceuticals Stock Briefly Spiked Today
Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Down 6.3%
Why Aurinia Pharmaceuticals Stock Is Plunging
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Down 4.1%
Why Aurinia Pharmaceuticals Stock Perked Up Today
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Company Calendar

Last Earnings
8/04/2022
Today
8/08/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.20
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+156.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-180,970,000.00
Net Margins
-178.32%
Pretax Margin
-177.46%

Debt

Sales & Book Value

Annual Sales
$45.60 million
Book Value
$3.69 per share

Miscellaneous

Free Float
136,642,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
0.95














AUPH Stock - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price forecast for 2022?

7 analysts have issued 12 month price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price forecasts range from $13.00 to $30.00. On average, they predict the company's stock price to reach $21.20 in the next year. This suggests a possible upside of 156.3% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How has Aurinia Pharmaceuticals' stock performed in 2022?

Aurinia Pharmaceuticals' stock was trading at $22.87 on January 1st, 2022. Since then, AUPH shares have decreased by 63.8% and is now trading at $8.27.
View the best growth stocks for 2022 here
.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AUPH earnings forecast
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative trailing twelve-month return on equity of 38.01%. During the same period last year, the business earned ($0.37) earnings per share.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.21%), HealthInvest Partners AB (0.16%), DnB Asset Management AS (0.10%), Victory Capital Management Inc. (0.07%), Bailard Inc. (0.05%) and Patriot Financial Group Insurance Agency LLC (0.03%). Insiders that own company stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends
.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUPH stock can currently be purchased for approximately $8.27.

How much money does Aurinia Pharmaceuticals make?

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.17 billion and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Aurinia Pharmaceuticals have?

Aurinia Pharmaceuticals employs 300 workers across the globe.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.

This page (NASDAQ:AUPH) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.